Skip to content

Inspection Record

Yuki Gosei Kogyo, Co., Ltd — FDA 483 Findings

US FDAInspected 2026-02-06Published 2026-11-05 3 findingsContamination controlMaterial and supplier controlDeviation, CAPA, and investigation

Inspectors Tamil ArasuThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

Procedures designed to prevent objectionable microorganisms in drug substance not required to be sterile are not effective.

2Material and supplier control

Your supplier qualifications are deficient.

3Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-11-05. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Yuki Gosei Kogyo, Co., Ltd findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.